Sectors
MLTX
MoonLake Immunotherapeutics
19.43
2 x 19.37
1 x 19.50
bid
ask
-
0.63
3.14%
09:54 AM
timesize
| Ytd | 47.42% | |
| 1y | -63.73% |
19.65
day range
20.00
5.95
52 week range
62.75
| Open | 19.90 | Prev Close | 20.06 | Low | 19.65 | High | 20.00 | Mkt Cap | 1.66B |
| Vol | 168.94K | Avg Vol | 1.10M | EPS | -3.87 | P/E | -5.18 | Forward P/E | -5.94 |
| Beta | 1.04 | Short Ratio | 5.02 | Inst. Own | 79.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.86 | 200-d Avg | 15.78 | 1yr Est | 28.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-04 | 2026-06 | -0.91 | N/A | N/A | N/A |
| 2026-05-11 | 2026-03 | -0.91 | -0.98 | -0.07 | -7.69% |
| 2026-02-25 | 2025-12 | -0.92 | -0.92 | N/A | N/A |
| 2025-11-05 | 2025-09 | -0.89 | -1.1 | -0.21 | -23.60% |
| 2025-08-05 | 2025-06 | -0.73 | -0.87 | -0.14 | -19.18% |
| 2025-05-12 | 2025-03 | -0.76 | -0.63 | 0.13 | 17.11% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-01 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-06-09 | BTIG | Upgrade | Buy | Buy |
| 2026-06-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-12 | Needham | Upgrade | Buy | Buy |
| 2026-05-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-30 | BTIG | Upgrade | Buy | Buy |
Profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-21 | BODENSTEDT MATTHIAS | Chief Financial Officer | 1.12M | Sale |
| 2026-03-30 | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-09-29 | CHEN BIHUA X. | Former | 0.00 | Sale |
| 2025-07-02 | MOUKHEIBIR CATHERINE | Director | 0.00 | Sale |
| 2026-06-16 | REICH KRISTIAN | Officer | 0.00 | Sale |
| 2026-06-30 | SANTOS DA SILVA JORGE | Chief Executive Officer | 2.88M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Bvf Inc | 16.00M | 0.00 | 21.74% |
| 2026-03-30 | Deep Track Capital, LP | 6.41M | 0.00 | 8.71% |
| 2026-03-30 | Cormorant Asset Management, LLC | 4.48M | 0.00 | 6.09% |
| 2026-03-30 | HHG PLC | 3.45M | 0.00 | 4.69% |
| 2026-03-30 | D. E. Shaw & Co LP | 2.39M | 0.00 | 3.25% |
| 2026-03-30 | MPM Oncology Impact Management LP | 1.81M | 0.00 | 2.46% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Jupiter Merian Glb Eq AbsRet I USD Acc | 1.18M | 0.00 | 1.62% |
| 2026-04-29 | T. Rowe Price Health Sciences | 939.23K | 0.00 | 1.29% |
| 2026-03-30 | Janus Henderson Hrzn Biotec E2 USD | 565.45K | 0.00 | 0.78% |
| 2026-01-30 | Rhenman Healthcare Equity L/S RC2 SEK | 364.00K | 0.00 | 0.50% |
| 2026-04-29 | T. Rowe Price Small-Cap Value | 271.43K | 0.00 | 0.37% |
| 2026-04-29 | BlackRock Health Sciences Opps Inv A | 161.39K | 0.00 | 0.22% |